Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler

Werewolf Therapeutics, Inc.

Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.
Hired Piper Sandler & Co. as exclusive financial advisor to assist in the strategic evaluation.
CEO Dan Hicklin cites INDUKINE and INDUCER platforms and clinical-stage candidates as core assets.
No defined timeline; company will not disclose further unless board approves specific action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.